Researchers develop heroin vaccine to fight the opioid crisis

Researchers with the U.S. Military HIV Research Program have developed an experimental heroin vaccine capable of preventing the drug from passing the blood-brain barrier in mice. Findings were published in the Journal of Medicinal Chemistry.

Amid the opioid epidemic, researchers have developed a heroin vaccine prevents the drug from affecting its user. The vaccine could be a step forward in reducing the number of addicted individuals as well as the overdose rate.

"By eliciting antibodies that bind with heroin in the blood, the vaccine aims to block the euphoria and addictive effects," said Gary Matyas, PhD, Chief of Adjuvants and Formulations for the U.S. Military Research Program (MHRP). "We hope to give people a window so they can overcome their addiction."

In the study, researchers explained how the vaccine produced antibodies against many of the commonly misused opioids including hydrocodone, oxycodone, hydromorphone, oxymorphone and codeine. Additionally, the study noted the vaccine should not be used with other drugs for opioid misuse like methadone and naltrexone because the antibodies do not cross-react.

"Although we are still in the early phase, this study suggests that vaccination can be used together with standard therapies to prevent the withdrawal and craving symptoms associated with opioid withdrawal," said Matyas.

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup